In the past 10 years, thrombolytics have become standard therapy for acute myocardial
infarction. Although the ability of streptokinase to lyse clot was first recognised in the 1930s …

Within a remarkably short time of the re-emergence of interest in thrombolytic treatment for
acute myocardial infarction the efficacy of this approach was confirmed in several large …

Pump failure is presently the leading cause of death in the coronary care unit in patient with
acute myocardial infarction. Furthermore followup studies have shown that left ventricular …

The beneficial effects of thrombolytic therapy in acute ischemic coronary syndromes, and
particularly in acute myocardial infarction, are now well established. The limited efficacy and …

Several large-scale, placebo-controlled trials with intravenous throm bolytic agents have
established a significant reduction (≥ 20%) of both early and late mortality in patients with …

Thrombolytic therapy is a practical, effective approach to the management of acute
myocardial infarction that is widely used in Europe today. Early European trials …

A consensus group convened under the auspices of the Ontario Medical Association
produced guidelines for the use of intravenous thrombolytic agents in acute myocardial …

Streptokinase and urokinase have proved to be useful in a limited number of clinical
conditions. Mainly because of the risk and unpredictability of bleeding with this first …

Trials of thrombolytic therapy have taught us that 1) lysis of hemostatic plugs, not
fibrinogenolysis, is the major cause of bleeding complications; 2) as currently reported …

Coronary thrombolysis revolutionized the treatment of acute myocardial infarction. Most of
the experience was obtained with intravenous use of streptokinase and tissue‐type …